View Future GrowthStageZero Life Sciences 과거 순이익 실적과거 기준 점검 0/6StageZero Life Sciences 의 수입은 연평균 -22.3%의 비율로 감소해 온 반면, Biotechs 산업은 연평균 17%의 비율로 증가했습니다. 매출은 연평균 36.4%의 비율로 증가해 왔습니다.핵심 정보-22.26%순이익 성장률24.83%주당순이익(EPS) 성장률Biotechs 산업 성장률-14.59%매출 성장률36.36%자기자본이익률n/a순이익률-418.65%최근 순이익 업데이트30 Sep 2023최근 과거 실적 업데이트공시 • Apr 03StageZero Life Sciences Ltd. to Report Q4, 2023 Results on May 31, 2024StageZero Life Sciences Ltd. announced that they will report Q4, 2023 results on May 31, 2024Reported Earnings • Nov 16Third quarter 2023 earnings released: US$0.01 loss per share (vs US$0 in 3Q 2022)Third quarter 2023 results: US$0.01 loss per share (further deteriorated from US$0 in 3Q 2022). Revenue: US$745.5k (down 6.7% from 3Q 2022). Net loss: US$821.9k (loss widened US$776.8k from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 60% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 15Second quarter 2023 earnings released: US$0.003 loss per share (vs US$0.013 loss in 2Q 2022)Second quarter 2023 results: US$0.003 loss per share (improved from US$0.013 loss in 2Q 2022). Revenue: US$793.3k (down 21% from 2Q 2022). Net loss: US$401.5k (loss narrowed 69% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 58% per year, which means it is significantly lagging earnings.Reported Earnings • May 18First quarter 2023 earnings released: US$0.02 loss per share (vs US$0.006 loss in 1Q 2022)First quarter 2023 results: US$0.02 loss per share (further deteriorated from US$0.006 loss in 1Q 2022). Revenue: US$778.5k (down 41% from 1Q 2022). Net loss: US$1.81m (loss widened 207% from 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 56% per year, which means it is performing significantly worse than earnings.공시 • May 16StageZero Life Sciences Ltd. to Report Q1, 2023 Results on May 15, 2023StageZero Life Sciences Ltd. announced that they will report Q1, 2023 results on May 15, 2023Reported Earnings • Nov 17Third quarter 2022 earnings released: EPS: US$0 (vs US$0.033 loss in 3Q 2021)Third quarter 2022 results: EPS: US$0 (improved from US$0.033 loss in 3Q 2021). Revenue: US$799.4k (up 17% from 3Q 2021). Net loss: US$45.1k (loss narrowed 98% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings.모든 업데이트 보기Recent updates공시 • May 08StageZero Life Sciences Ltd. announced that it expects to receive CAD 2 million in fundingStageZero Life Sciences Ltd. announced a private placement transaction of of either, or a combination of: (i) up to CAD 2,000,000 of non-convertible notes bearing an interest rate of between 12 % to 14 per % per annum; or a convertible debt offering up to CAD 800,000 of units; each unit consisting of CAD 1,000 principal amount of unsecured convertible debentures bearing an interest rate of 8 % per annum, and 12,500 common share purchase warrants, provided that the aggregate gross proceeds from the debt offering and the convertible debt offering would not exceed CAD 2,000,000 on a combined basis on May 7, 2025. Each warrant is exercisable for one common share of the issuer. The principal amount of the convertible debentures may be converted by the holders into common shares at a floor conversion price to be determined based on the market price of the issuer's common shares on the Toronto Stock Exchange following recommencement of trading of the issuer's common shares on TSX (as required by applicable TSX policies). Each warrant shall be exercisable to purchase a common share at an exercise price that will be three cents higher than the market price for a period of 18 months. The proposed financing is subject to the approval of the TSX.공시 • Apr 03StageZero Life Sciences Ltd. to Report Q4, 2023 Results on May 31, 2024StageZero Life Sciences Ltd. announced that they will report Q4, 2023 results on May 31, 2024Reported Earnings • Nov 16Third quarter 2023 earnings released: US$0.01 loss per share (vs US$0 in 3Q 2022)Third quarter 2023 results: US$0.01 loss per share (further deteriorated from US$0 in 3Q 2022). Revenue: US$745.5k (down 6.7% from 3Q 2022). Net loss: US$821.9k (loss widened US$776.8k from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 60% per year, which means it is significantly lagging earnings.공시 • Nov 08StageZero Life Sciences, Ltd. Clinical Business Introduces Fourth Pillar to Cancer OfferingsStageZero Life Sciences Ltd. announced that its Clinical Business, Care Oncology, has added the fourth of a series of new program offerings. Pinky Jimenez-Agrawal, with WellnessScript, will provide mental health support specifically for cancer patients at twice-monthly clinics. The first clinic is Thursday November 9, 2023 and is open to patients globally. Screening to find cancer early is the first pillar (AristotleTM); adjunctive treatment with the Care Oncology Protocol is the second; nutritional guidance tailored to the type and stage of the cancer is the third pillar and mental health support is the fourth pillar. The Company believes that these additional offerings present an excellent entry point for cancer patients to be introduced to the full Care Oncology program. One in three patients with cancer have challenges with mental health: up to 25% of cancer survivors suffer from depression and up to 45% with anxiety. Supporting individuals on their journey towards recovery as well as offering help to terminally ill patients and their families as they prepare for death, is a key aspect of her work. She runs bimonthly drop-in sessions, and provides psychological support on a 1:1 basis, for the members of a leukaemia charity. As a volunteer therapist for Cruse Bereavement Care, she provides counselling to children and young adults. She's an ACT practitioner and a DBT informed therapist. She uses a combination of therapies and mindfulness-based interventions. Her work helps individuals build on their strengths by helping them learn new skills, expand from their own experience and teach strategies to enable them to cope with their issues and develop better well-being habits. The program will be offered virtually, twice a month. The program is open to anyone, not just Care Oncology patients and with times to allow global participation. Interested individuals can sign up at [1]. Participants will pay directly for each session. Care Oncology offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Care Oncology has been treating cancer patients since 2013 using patented COC Protocol™?. It is an individualized therapeutic approach which seeks to simultaneously target multiple metabolic cancer pathways and is intended for adjunctive administration alongside standard-of-care cancer therapy. The aim is to restrict cancer cell energy supply and use. In addition to the COC Protocol, Care Oncology offers the AVRT preventative program. All of the Care Oncology programs are managed by a multi-disciplinary team that is overseen by Oncologists and includes Nurse practitioners and Metabolic Specialists.공시 • Oct 21Stagezero Life Sciences, Ltd. Clinical Business Introduces Third Pillar to Cancer OfferingsStageZero Life Sciences Ltd. announced that its Clinical Business Care Oncology, has added the first of a series of new program offerings. The Source Functional Nutrition group will provide educational sessions, live cooking lessons, bi-weekly drop in Cafe's, 1:1 consultation as well as a library of recipes and videos. The program initiatives Friday, October 27th. Screening to find cancer early is the first pillar (AristotleTM); adjunctive treatment with the CareOncology Protocol is the second; nutritional guidance tailored to the type and stage of the cancer is the third pillar. "25-80% of cancer patients, depending on their age and the type and stage of thecancer, suffer from mal nutrition. This problem has become much more acute since the COVID pandemic as treatment options were delayed and access curtailed. Chemotherapy patients, especially, rely on Oncology Nutrition to help with physical strength and assistance during treatment. Nutritional screening and evaluation, as well as detailed nutritional guidance, are essential to assist with a good outcome" said James Howard-Tripp, Chairman and CEO of StageZero Life Sciences. The Source Functional Nutritional offering provides cancer specific nutritional guidance with group information sessions, cooking lessons and one on one sessions. Diet is key to supporting a patient's ability to manage treatment and retain strength. dietary guidance can differ between cancer type and stage of treatment. TheSource program will show participants how to navigate this with concrete tools and recipes. Care Oncology offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Care Oncology has been treating cancer patients since 2013 using patented COC Protocol™?. It is an individualized therapeutic approach which seeks to simultaneously target multiple metabolic cancer pathways and is intended for adjunctive administration alongside standard-of-care cancer therapy. The aim is to restrict cancer cell energy supply and use. In addition to the COC Protocol, Care Oncology offers the AVRT program. All of the Care Oncology programs are managed by a multi-disciplinary team that is overseen by an Oncologist and includes Nurse Practitioners and Metabolic Specialists. Care Oncology Clinics also offers AVRT a Physician-Led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Aristotle®? is processed at the Company's clinical laboratory, StageZero Life Sciences Inc., a CAP accredited and CLIA certified high-complex cancer.Reported Earnings • Aug 15Second quarter 2023 earnings released: US$0.003 loss per share (vs US$0.013 loss in 2Q 2022)Second quarter 2023 results: US$0.003 loss per share (improved from US$0.013 loss in 2Q 2022). Revenue: US$793.3k (down 21% from 2Q 2022). Net loss: US$401.5k (loss narrowed 69% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 58% per year, which means it is significantly lagging earnings.Reported Earnings • May 18First quarter 2023 earnings released: US$0.02 loss per share (vs US$0.006 loss in 1Q 2022)First quarter 2023 results: US$0.02 loss per share (further deteriorated from US$0.006 loss in 1Q 2022). Revenue: US$778.5k (down 41% from 1Q 2022). Net loss: US$1.81m (loss widened 207% from 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 56% per year, which means it is performing significantly worse than earnings.공시 • May 16StageZero Life Sciences Ltd. to Report Q1, 2023 Results on May 15, 2023StageZero Life Sciences Ltd. announced that they will report Q1, 2023 results on May 15, 2023Reported Earnings • Nov 17Third quarter 2022 earnings released: EPS: US$0 (vs US$0.033 loss in 3Q 2021)Third quarter 2022 results: EPS: US$0 (improved from US$0.033 loss in 3Q 2021). Revenue: US$799.4k (up 17% from 3Q 2021). Net loss: US$45.1k (loss narrowed 98% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings.Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 9 highly experienced directors. Member of Colorectal Cancer Clinical Advisory Board Larry Cohen was the last director to join the board, commencing their role in 2008. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Reported Earnings • Aug 17Second quarter 2022 earnings released: US$0.01 loss per share (vs US$0.067 profit in 2Q 2021)Second quarter 2022 results: US$0.01 loss per share (down from US$0.067 profit in 2Q 2021). Revenue: US$998.2k (up 147% from 2Q 2021). Net loss: US$1.28m (down 130% from profit in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings.Reported Earnings • May 18First quarter 2022 earnings released: US$0.01 loss per share (vs US$0.12 loss in 1Q 2021)First quarter 2022 results: US$0.01 loss per share (up from US$0.12 loss in 1Q 2021). Revenue: US$1.32m (down 47% from 1Q 2021). Net loss: US$590.5k (loss narrowed 92% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings.Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 9 highly experienced directors. Member of Colorectal Cancer Clinical Advisory Board Larry Cohen was the last director to join the board, commencing their role in 2008. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Reported Earnings • Apr 02Full year 2021 earnings released: US$0.11 loss per share (vs US$0.15 loss in FY 2020)Full year 2021 results: US$0.11 loss per share. Revenue: US$5.07m (up 22% from FY 2020). Net loss: US$7.48m (loss widened 9.0% from FY 2020).Reported Earnings • Nov 17Third quarter 2021 earnings released: US$0.02 loss per share (vs US$0.11 loss in 3Q 2020)The company reported a soft third quarter result with weaker revenues and control over costs, although losses reduced. Third quarter 2021 results: Revenue: US$684.3k (down 53% from 3Q 2020). Net loss: US$2.22m (loss narrowed 52% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has increased by 68% per year, which means it is tracking significantly ahead of earnings growth.Executive Departure • Sep 01Interim Chief Financial Officer Carl Solomon has left the companyDuring their tenure, earnings grew by 20% annually compared to the industry average of 20%. On the 28th of August, Carl Solomon left the company after 2.9 in the role. We don't have any record of a personal shareholding under Carl's name. Carl is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 3.92 years.Reported Earnings • Aug 18Second quarter 2021 earnings released: EPS US$0.05 (vs US$0.006 loss in 2Q 2020)Second quarter 2021 results: Revenue: US$404.7k (up US$341.3k from 2Q 2020). Net income: US$4.33m (up US$4.60m from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth.Reported Earnings • May 18First quarter 2021 earnings releasedThe company reported a solid first quarter result with improved revenues and control over costs, although losses increased. First quarter 2021 results: Revenue: US$2.48m (up US$2.47m from 1Q 2020). Net loss: US$7.30m (loss widened 170% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.Reported Earnings • Apr 04Full year 2020 earnings releasedThe company reported a solid full year result with improved revenues and control over costs, although losses increased. Full year 2020 results: Revenue: US$4.15m (up US$4.01m from FY 2019). Net loss: US$6.86m (loss widened 97% from FY 2019). Over the last 3 years on average, earnings per share has increased by 31% per year whereas the company’s share price has increased by 36% per year.Is New 90 Day High Low • Feb 18New 90-day high: €0.90The company is up 95% from its price of €0.46 on 19 November 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 15% over the same period.Is New 90 Day High Low • Jan 14New 90-day high: €0.60The company is up 9.0% from its price of €0.56 on 15 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 1.0% over the same period.Is New 90 Day High Low • Dec 17New 90-day low: €0.39The company is down 25% from its price of €0.51 on 18 September 2020. The German market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 9.0% over the same period.Is New 90 Day High Low • Sep 19New 90-day high: €0.51The company is up 929% from its price of €0.05 on 19 June 2020. The German market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 8.0% over the same period.매출 및 비용 세부 내역StageZero Life Sciences가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이DB:61N1 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비30 Sep 233-135030 Jun 233-125031 Mar 233-136031 Dec 224-117030 Sep 225-48130 Jun 225-69131 Mar 224-19131 Dec 215-78130 Sep 216-77130 Jun 217-77031 Mar 217-125031 Dec 204-74030 Sep 202-63030 Jun 200-13031 Mar 200-14031 Dec 190-34030 Sep 190-34030 Jun 190-53031 Mar 190-84031 Dec 180-44030 Sep 180-44030 Jun 180-44031 Mar 180-24031 Dec 170-34030 Sep 171-24030 Jun 171-44031 Mar 171-54031 Dec 161-64030 Sep 161-84030 Jun 160-83031 Mar 160-83031 Dec 150-63030 Sep 151-74030 Jun 153-64031 Mar 153-74031 Dec 142-74030 Sep 142-74030 Jun 141-104031 Mar 140-94031 Dec 130-94030 Sep 130-840양질의 수익: 61N1 은(는) 현재 수익성이 없습니다.이익 마진 증가: 61N1는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 61N1은 수익성이 없으며 지난 5년 동안 손실이 연평균 22.3% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 61N1의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: 61N1은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(7.2%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: 61N1의 부채가 자산을 초과하여 자본 수익률을 계산하기 어렵습니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/07/07 19:25종가2024/04/09 00:00수익2023/09/30연간 수익2022/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스StageZero Life Sciences Ltd.는 3명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Douglas LoeCantor Fitzgerald Canada CorporationChris ThompsoneResearch CorporationClaude CamiréParadigm Capital, Inc.
공시 • Apr 03StageZero Life Sciences Ltd. to Report Q4, 2023 Results on May 31, 2024StageZero Life Sciences Ltd. announced that they will report Q4, 2023 results on May 31, 2024
Reported Earnings • Nov 16Third quarter 2023 earnings released: US$0.01 loss per share (vs US$0 in 3Q 2022)Third quarter 2023 results: US$0.01 loss per share (further deteriorated from US$0 in 3Q 2022). Revenue: US$745.5k (down 6.7% from 3Q 2022). Net loss: US$821.9k (loss widened US$776.8k from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 60% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 15Second quarter 2023 earnings released: US$0.003 loss per share (vs US$0.013 loss in 2Q 2022)Second quarter 2023 results: US$0.003 loss per share (improved from US$0.013 loss in 2Q 2022). Revenue: US$793.3k (down 21% from 2Q 2022). Net loss: US$401.5k (loss narrowed 69% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 58% per year, which means it is significantly lagging earnings.
Reported Earnings • May 18First quarter 2023 earnings released: US$0.02 loss per share (vs US$0.006 loss in 1Q 2022)First quarter 2023 results: US$0.02 loss per share (further deteriorated from US$0.006 loss in 1Q 2022). Revenue: US$778.5k (down 41% from 1Q 2022). Net loss: US$1.81m (loss widened 207% from 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 56% per year, which means it is performing significantly worse than earnings.
공시 • May 16StageZero Life Sciences Ltd. to Report Q1, 2023 Results on May 15, 2023StageZero Life Sciences Ltd. announced that they will report Q1, 2023 results on May 15, 2023
Reported Earnings • Nov 17Third quarter 2022 earnings released: EPS: US$0 (vs US$0.033 loss in 3Q 2021)Third quarter 2022 results: EPS: US$0 (improved from US$0.033 loss in 3Q 2021). Revenue: US$799.4k (up 17% from 3Q 2021). Net loss: US$45.1k (loss narrowed 98% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings.
공시 • May 08StageZero Life Sciences Ltd. announced that it expects to receive CAD 2 million in fundingStageZero Life Sciences Ltd. announced a private placement transaction of of either, or a combination of: (i) up to CAD 2,000,000 of non-convertible notes bearing an interest rate of between 12 % to 14 per % per annum; or a convertible debt offering up to CAD 800,000 of units; each unit consisting of CAD 1,000 principal amount of unsecured convertible debentures bearing an interest rate of 8 % per annum, and 12,500 common share purchase warrants, provided that the aggregate gross proceeds from the debt offering and the convertible debt offering would not exceed CAD 2,000,000 on a combined basis on May 7, 2025. Each warrant is exercisable for one common share of the issuer. The principal amount of the convertible debentures may be converted by the holders into common shares at a floor conversion price to be determined based on the market price of the issuer's common shares on the Toronto Stock Exchange following recommencement of trading of the issuer's common shares on TSX (as required by applicable TSX policies). Each warrant shall be exercisable to purchase a common share at an exercise price that will be three cents higher than the market price for a period of 18 months. The proposed financing is subject to the approval of the TSX.
공시 • Apr 03StageZero Life Sciences Ltd. to Report Q4, 2023 Results on May 31, 2024StageZero Life Sciences Ltd. announced that they will report Q4, 2023 results on May 31, 2024
Reported Earnings • Nov 16Third quarter 2023 earnings released: US$0.01 loss per share (vs US$0 in 3Q 2022)Third quarter 2023 results: US$0.01 loss per share (further deteriorated from US$0 in 3Q 2022). Revenue: US$745.5k (down 6.7% from 3Q 2022). Net loss: US$821.9k (loss widened US$776.8k from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 60% per year, which means it is significantly lagging earnings.
공시 • Nov 08StageZero Life Sciences, Ltd. Clinical Business Introduces Fourth Pillar to Cancer OfferingsStageZero Life Sciences Ltd. announced that its Clinical Business, Care Oncology, has added the fourth of a series of new program offerings. Pinky Jimenez-Agrawal, with WellnessScript, will provide mental health support specifically for cancer patients at twice-monthly clinics. The first clinic is Thursday November 9, 2023 and is open to patients globally. Screening to find cancer early is the first pillar (AristotleTM); adjunctive treatment with the Care Oncology Protocol is the second; nutritional guidance tailored to the type and stage of the cancer is the third pillar and mental health support is the fourth pillar. The Company believes that these additional offerings present an excellent entry point for cancer patients to be introduced to the full Care Oncology program. One in three patients with cancer have challenges with mental health: up to 25% of cancer survivors suffer from depression and up to 45% with anxiety. Supporting individuals on their journey towards recovery as well as offering help to terminally ill patients and their families as they prepare for death, is a key aspect of her work. She runs bimonthly drop-in sessions, and provides psychological support on a 1:1 basis, for the members of a leukaemia charity. As a volunteer therapist for Cruse Bereavement Care, she provides counselling to children and young adults. She's an ACT practitioner and a DBT informed therapist. She uses a combination of therapies and mindfulness-based interventions. Her work helps individuals build on their strengths by helping them learn new skills, expand from their own experience and teach strategies to enable them to cope with their issues and develop better well-being habits. The program will be offered virtually, twice a month. The program is open to anyone, not just Care Oncology patients and with times to allow global participation. Interested individuals can sign up at [1]. Participants will pay directly for each session. Care Oncology offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Care Oncology has been treating cancer patients since 2013 using patented COC Protocol™?. It is an individualized therapeutic approach which seeks to simultaneously target multiple metabolic cancer pathways and is intended for adjunctive administration alongside standard-of-care cancer therapy. The aim is to restrict cancer cell energy supply and use. In addition to the COC Protocol, Care Oncology offers the AVRT preventative program. All of the Care Oncology programs are managed by a multi-disciplinary team that is overseen by Oncologists and includes Nurse practitioners and Metabolic Specialists.
공시 • Oct 21Stagezero Life Sciences, Ltd. Clinical Business Introduces Third Pillar to Cancer OfferingsStageZero Life Sciences Ltd. announced that its Clinical Business Care Oncology, has added the first of a series of new program offerings. The Source Functional Nutrition group will provide educational sessions, live cooking lessons, bi-weekly drop in Cafe's, 1:1 consultation as well as a library of recipes and videos. The program initiatives Friday, October 27th. Screening to find cancer early is the first pillar (AristotleTM); adjunctive treatment with the CareOncology Protocol is the second; nutritional guidance tailored to the type and stage of the cancer is the third pillar. "25-80% of cancer patients, depending on their age and the type and stage of thecancer, suffer from mal nutrition. This problem has become much more acute since the COVID pandemic as treatment options were delayed and access curtailed. Chemotherapy patients, especially, rely on Oncology Nutrition to help with physical strength and assistance during treatment. Nutritional screening and evaluation, as well as detailed nutritional guidance, are essential to assist with a good outcome" said James Howard-Tripp, Chairman and CEO of StageZero Life Sciences. The Source Functional Nutritional offering provides cancer specific nutritional guidance with group information sessions, cooking lessons and one on one sessions. Diet is key to supporting a patient's ability to manage treatment and retain strength. dietary guidance can differ between cancer type and stage of treatment. TheSource program will show participants how to navigate this with concrete tools and recipes. Care Oncology offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Care Oncology has been treating cancer patients since 2013 using patented COC Protocol™?. It is an individualized therapeutic approach which seeks to simultaneously target multiple metabolic cancer pathways and is intended for adjunctive administration alongside standard-of-care cancer therapy. The aim is to restrict cancer cell energy supply and use. In addition to the COC Protocol, Care Oncology offers the AVRT program. All of the Care Oncology programs are managed by a multi-disciplinary team that is overseen by an Oncologist and includes Nurse Practitioners and Metabolic Specialists. Care Oncology Clinics also offers AVRT a Physician-Led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Aristotle®? is processed at the Company's clinical laboratory, StageZero Life Sciences Inc., a CAP accredited and CLIA certified high-complex cancer.
Reported Earnings • Aug 15Second quarter 2023 earnings released: US$0.003 loss per share (vs US$0.013 loss in 2Q 2022)Second quarter 2023 results: US$0.003 loss per share (improved from US$0.013 loss in 2Q 2022). Revenue: US$793.3k (down 21% from 2Q 2022). Net loss: US$401.5k (loss narrowed 69% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 58% per year, which means it is significantly lagging earnings.
Reported Earnings • May 18First quarter 2023 earnings released: US$0.02 loss per share (vs US$0.006 loss in 1Q 2022)First quarter 2023 results: US$0.02 loss per share (further deteriorated from US$0.006 loss in 1Q 2022). Revenue: US$778.5k (down 41% from 1Q 2022). Net loss: US$1.81m (loss widened 207% from 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 56% per year, which means it is performing significantly worse than earnings.
공시 • May 16StageZero Life Sciences Ltd. to Report Q1, 2023 Results on May 15, 2023StageZero Life Sciences Ltd. announced that they will report Q1, 2023 results on May 15, 2023
Reported Earnings • Nov 17Third quarter 2022 earnings released: EPS: US$0 (vs US$0.033 loss in 3Q 2021)Third quarter 2022 results: EPS: US$0 (improved from US$0.033 loss in 3Q 2021). Revenue: US$799.4k (up 17% from 3Q 2021). Net loss: US$45.1k (loss narrowed 98% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings.
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 9 highly experienced directors. Member of Colorectal Cancer Clinical Advisory Board Larry Cohen was the last director to join the board, commencing their role in 2008. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Reported Earnings • Aug 17Second quarter 2022 earnings released: US$0.01 loss per share (vs US$0.067 profit in 2Q 2021)Second quarter 2022 results: US$0.01 loss per share (down from US$0.067 profit in 2Q 2021). Revenue: US$998.2k (up 147% from 2Q 2021). Net loss: US$1.28m (down 130% from profit in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings.
Reported Earnings • May 18First quarter 2022 earnings released: US$0.01 loss per share (vs US$0.12 loss in 1Q 2021)First quarter 2022 results: US$0.01 loss per share (up from US$0.12 loss in 1Q 2021). Revenue: US$1.32m (down 47% from 1Q 2021). Net loss: US$590.5k (loss narrowed 92% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings.
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 9 highly experienced directors. Member of Colorectal Cancer Clinical Advisory Board Larry Cohen was the last director to join the board, commencing their role in 2008. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Reported Earnings • Apr 02Full year 2021 earnings released: US$0.11 loss per share (vs US$0.15 loss in FY 2020)Full year 2021 results: US$0.11 loss per share. Revenue: US$5.07m (up 22% from FY 2020). Net loss: US$7.48m (loss widened 9.0% from FY 2020).
Reported Earnings • Nov 17Third quarter 2021 earnings released: US$0.02 loss per share (vs US$0.11 loss in 3Q 2020)The company reported a soft third quarter result with weaker revenues and control over costs, although losses reduced. Third quarter 2021 results: Revenue: US$684.3k (down 53% from 3Q 2020). Net loss: US$2.22m (loss narrowed 52% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has increased by 68% per year, which means it is tracking significantly ahead of earnings growth.
Executive Departure • Sep 01Interim Chief Financial Officer Carl Solomon has left the companyDuring their tenure, earnings grew by 20% annually compared to the industry average of 20%. On the 28th of August, Carl Solomon left the company after 2.9 in the role. We don't have any record of a personal shareholding under Carl's name. Carl is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 3.92 years.
Reported Earnings • Aug 18Second quarter 2021 earnings released: EPS US$0.05 (vs US$0.006 loss in 2Q 2020)Second quarter 2021 results: Revenue: US$404.7k (up US$341.3k from 2Q 2020). Net income: US$4.33m (up US$4.60m from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth.
Reported Earnings • May 18First quarter 2021 earnings releasedThe company reported a solid first quarter result with improved revenues and control over costs, although losses increased. First quarter 2021 results: Revenue: US$2.48m (up US$2.47m from 1Q 2020). Net loss: US$7.30m (loss widened 170% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Apr 04Full year 2020 earnings releasedThe company reported a solid full year result with improved revenues and control over costs, although losses increased. Full year 2020 results: Revenue: US$4.15m (up US$4.01m from FY 2019). Net loss: US$6.86m (loss widened 97% from FY 2019). Over the last 3 years on average, earnings per share has increased by 31% per year whereas the company’s share price has increased by 36% per year.
Is New 90 Day High Low • Feb 18New 90-day high: €0.90The company is up 95% from its price of €0.46 on 19 November 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 15% over the same period.
Is New 90 Day High Low • Jan 14New 90-day high: €0.60The company is up 9.0% from its price of €0.56 on 15 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 1.0% over the same period.
Is New 90 Day High Low • Dec 17New 90-day low: €0.39The company is down 25% from its price of €0.51 on 18 September 2020. The German market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 9.0% over the same period.
Is New 90 Day High Low • Sep 19New 90-day high: €0.51The company is up 929% from its price of €0.05 on 19 June 2020. The German market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 8.0% over the same period.